Apnimed CEO reports stock option reclassification

Apnimed, Inc. director and Chief Executive Officer Kevin Robert Lind reported several derivative transactions in stock options on Class A Common Stock and Common Stock.

Rhea-AI Filing Summary

Apnimed, Inc. director and Chief Executive Officer Kevin Robert Lind reported several derivative transactions in stock options on Class A Common Stock and Common Stock. On 2026-08-03, existing options tied to Class A Common Stock were disposed of to the issuer and corresponding options on Common Stock were acquired in equal amounts, reflecting a reclassification exempt under Rule 16b-7 and Rule 16b-3. The affected grants cover 74,128 options at an exercise price of $9.50 expiring 2035-03-06, and blocks of 1,186,278 and 108,916 options at exercise prices of $8.15 and $16.00, both expiring 2036-06-23 and 2036-07-29, respectively. Footnotes describe time-based vesting over four years, contingent on Lind’s continuous service to Apnimed.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Lind Kevin Robert

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy) F1, F2	74,128	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F2	74,128	$0.00	$0.00
Disposition	Stock Option (Right to Buy) F1, F3	1,186,278	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F3	1,186,278	$0.00	$0.00
Disposition	Stock Option (Right to Buy) F1, F3	108,916	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F3	108,916	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F3	108,916	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,369,322 contracts (Direct)

Footnotes (3)

1. F1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
2. F2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
3. F3. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Options at $9.50: 74,128 options at $9.5000 per share Options at $8.15: 1,186,278 options at $8.1500 per share Options at $16.00: 108,916 options at $16.0000 per share +3 more

6 metrics

Options at $9.50 74,128 options at $9.5000 per share Stock options expiring 2035-03-06, reclassified from Class A Common Stock to Common Stock

Options at $8.15 1,186,278 options at $8.1500 per share Stock options expiring 2036-06-23, tied to reclassification and vesting per footnote F3

Options at $16.00 108,916 options at $16.0000 per share Stock options expiring 2036-07-29, reported on 2026-07-30 and 2026-08-03

Reclassified option block 3 paired D/A transactions Equal dispositions and acquisitions of options reflecting Class A to Common Stock reclassification

Vesting start (F2) 12 months after March 6, 2025 25% of $9.50 options vest after this period, then quarterly over 36 months

Vesting start (F3) 12 months after June 1, 2026 25% of certain options vest after this date, then monthly over 36 months

Key Terms

Rule 16b-7, Rule 16b-3, continuous service, Class A Common Stock

4 terms

Rule 16b-7 regulatory

"reclassification exempt under Rule 16b-7 and Rule 16b-3"

A U.S. Securities and Exchange Commission safe-harbor rule that shields corporate insiders (officers, directors and large shareholders) from automatic short-swing profit claims when they buy or sell their company’s stock under a pre-approved, written plan that follows specific timing and nondiscretionary rules. For investors, the rule matters because it distinguishes routine, formula-driven insider transactions from opportunistic trades that could trigger automatic profit recoveries—think of it as an approved autopilot for insider trading that reduces legal uncertainty when the plan’s conditions are met.

Rule 16b-3 regulatory

"reclassification exempt under Rule 16b-7 and Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

continuous service financial

"vest and become exercisable when the Reporting Person completes twelve months of continuous service"

Class A Common Stock financial

"each share of Class A Common Stock was reclassified into one share of Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Apnimed (APMD) CEO Kevin Robert Lind report in this Form 4?

Kevin Robert Lind reported stock option transactions involving the reclassification of options from Class A Common Stock to Common Stock, with equal numbers disposed to the issuer and acquired, reflecting an exempt reclassification under Rule 16b-7 and Rule 16b-3.

How many Apnimed (APMD) options at $8.15 and $16.00 were affected?

Lind’s filing shows 1,186,278 stock options at an exercise price of $8.15 and 108,916 options at $16.00, all tied to a reclassification from Class A Common Stock to Common Stock, with matched dispositions and acquisitions reported.

What is the vesting schedule for the $9.50 Apnimed (APMD) stock options?

For the $9.50 options on 74,128 shares, 25% vest after twelve months of continuous service from March 6, 2025, with the remaining 75% vesting in substantially equal quarterly installments over the following 36 months, subject to continued service.

What is the vesting schedule for the newer Apnimed (APMD) option grants?

For options footnoted with F3, 25% vest after twelve months of continuous service from June 1, 2026, and the remaining 75% vest in substantially equal monthly installments over the next 36 months, conditioned on Lind’s continuous service to Apnimed.

Were Apnimed (APMD) CEO transactions under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and the footnotes do not reference any trading plan. The reported stock option reclassification and vesting terms are therefore not described as occurring under a pre-arranged Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/09/2026 - 02:00 PM Accepted by SEC EDGAR 08/03/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last) (First) (Middle)

APNIMED, INC.

39 JOHN F. KENNEDY STREET, 4TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apnimed, Inc. [ APMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.5	08/03/2026		D(1)			74,128	(2)	03/06/2035	Class A Common Stock	74,128	$0	0	D
Stock Option (Right to Buy)	$9.5	08/03/2026		A(1)		74,128		(2)	03/06/2035	Common Stock	74,128	$0	74,128	D
Stock Option (Right to Buy)	$8.15	08/03/2026		D(1)			1,186,278	(3)	06/23/2036	Class A Common Stock	1,186,278	$0	0	D
Stock Option (Right to Buy)	$8.15	08/03/2026		A(1)		1,186,278		(3)	06/23/2036	Common Stock	1,186,278	$0	1,186,278	D
Stock Option (Right to Buy)	$16	07/30/2026		A		108,916		(3)	07/29/2036	Class A Common Stock	108,916	$0	108,916	D
Stock Option (Right to Buy)	$16	08/03/2026		D(1)			108,916	(3)	07/29/2036	Class A Common Stock	108,916	$0	0	D
Stock Option (Right to Buy)	$16	08/03/2026		A(1)		108,916		(3)	07/29/2036	Common Stock	108,916	$0	108,916	D

Explanation of Responses:

1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.

2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/Kevin R. Lind, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)